Literature DB >> 6737074

Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.

P Allweiss, G D Braunstein, A Katz, A Waxman.   

Abstract

During a 4-yr period, ten of 87 patients (11.5%) who received therapeutic doses of radioactive iodine (I-131) for thyroid carcinoma developed acute and/or chronic sialadenitis involving the parotid (five patients) or submandibular (four patients) glands, or both (one patient). Nine of the 10 patients had received prior I-131 therapy; the precipitating I-131 dose varied between 10 and 164 mCi. Onset of symptoms occurred between 1 day and 6 mo following therapy and the duration varied from 3 wk to 21/2 yr. This complication occurs more often than has been appreciated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6737074

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  [The aftercare of radiotherapy patients. The Radiation Protection Commission, the Federal Ministry for the Environment, Nature Protection and Reactor Safety].

Authors:  T Herrmann
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

2.  Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?

Authors:  Colleen M Kiernan; Alexander A Parikh; Lee L Parks; Carmen C Solórzano
Journal:  J Am Coll Surg       Date:  2014-12-17       Impact factor: 6.113

3.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

4.  The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Authors:  Walter Jentzen; Dorothee Balschuweit; Jochen Schmitz; Lutz Freudenberg; Ernst Eising; Thomas Hilbel; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

5.  Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.

Authors:  Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves
Journal:  J Cancer Surviv       Date:  2020-06-06       Impact factor: 4.442

6.  Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).

Authors:  Marta E Gonzalez; Thomas Jose Eluvathingal Muttikkal; Patrice K Rehm
Journal:  J Radiol Case Rep       Date:  2015-06-30

7.  Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia.

Authors:  Mihir K Bhayani; Varun Acharya; Suchada Kongkiatkamon; Sally Farah; Dianna B Roberts; Jennifer Sterba; Mark S Chambers; Stephen Y Lai
Journal:  Thyroid       Date:  2015-05-15       Impact factor: 6.568

8.  Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Authors:  Toshiyuki Ikeoka; Takao Ando; Misa Imaizumi; Ikuko Ueki; Toshiro Usa; Atsushi Kawakami
Journal:  Endocrine       Date:  2014-05       Impact factor: 3.633

9.  Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues.

Authors:  R Bruno; P Giannasio; G Ronga; E Baudin; J P Travagli; D Russo; S Filetti; M Schlumberger
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

10.  Significance of Salivary Gland Radioiodine Retention on Post-ablation (131)I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma.

Authors:  Kyung Sook Jo; Young-Sil An; Su Jin Lee; Euy-Young Soh; Jeonghun Lee; Yoon-Sok Chung; Dae Jung Kim; Seok-Ho Yoon; Dong Hyun Lee; Joon-Kee Yoon
Journal:  Nucl Med Mol Imaging       Date:  2014-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.